These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 34199035)

  • 1. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update.
    Hliwa A; Ramos-Molina B; Laski D; Mika A; Sledzinski T
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34199035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.
    Notarnicola M; Osella AR; Caruso MG; Pesole PL; Lippolis A; Tutino V; Bonfiglio C; De Nunzio V; Scavo MP; Mirizzi A; Franco I; Lippolis T; D'Alessandro R; Refolo MG; Messa C
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer surveillance in non-alcoholic fatty liver disease: A potential role for lipidomics.
    Best J; Bechmann LP
    EBioMedicine; 2021 Dec; 74():103711. PubMed ID: 34800903
    [No Abstract]   [Full Text] [Related]  

  • 10. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
    Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the microbiome in NAFLD and NASH.
    Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
    EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagy, NAFLD and NAFLD-Related HCC.
    Wu WKK; Zhang L; Chan MTV
    Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomechanics of cultured hepatic cells during different steatogenic hits.
    Baldini F; Bartolozzi A; Ardito M; Voci A; Portincasa P; Vassalli M; Vergani L
    J Mech Behav Biomed Mater; 2019 Sep; 97():296-305. PubMed ID: 31151002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients.
    Chiappini F; Coilly A; Kadar H; Gual P; Tran A; Desterke C; Samuel D; Duclos-Vallée JC; Touboul D; Bertrand-Michel J; Brunelle A; Guettier C; Le Naour F
    Sci Rep; 2017 Apr; 7():46658. PubMed ID: 28436449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.
    Lau JK; Zhang X; Yu J
    J Pathol; 2017 Jan; 241(1):36-44. PubMed ID: 27757953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling.
    Sunami Y
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity.
    Park SH; Lee JE; Lee SM; Lee J; Seo CS; Hwang GS; Jung J
    J Ethnopharmacol; 2020 Oct; 260():112999. PubMed ID: 32454173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Zhang C; Wang P; Li Y; Huang C; Ni W; Chen Y; Shi J; Chen G; Hu X; Ye M; Duan S; Wang K
    Anat Rec (Hoboken); 2019 Feb; 302(2):193-200. PubMed ID: 30312023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.